The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 19, 2024
Filed:
Jun. 09, 2022
Applicant:
Gilead Sciences, Inc., Foster City, CA (US);
Inventors:
Thomas F. Kenney, Seattle, WA (US);
Clinton K. Matson, Redmond, WA (US);
Chandrasekar Venkataramani, San Carlos, CA (US);
Assignee:
Gilead Sciences, Inc., Foster City, CA (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 47/68 (2017.01); A61K 31/519 (2006.01); A61K 31/553 (2006.01); A61P 11/00 (2006.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01);
U.S. Cl.
CPC ...
A61K 47/6851 (2017.08); A61K 31/519 (2013.01); A61K 31/553 (2013.01); A61K 47/6803 (2017.08); A61P 11/00 (2018.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01);
Abstract
The present disclosure generally relates to methods of treating or preventing cancer by administering an MCL-1 inhibitor and an antibody-drug conjugate, and optionally one or more additional anti-cancer agents. In particular, the MCL-1 inhibitor can be a compound of formula (I), (II) or (III), or compound A. The antibody-drug conjugate can comprises an anti-Trop-2 antibody and an anti-cancer agent (e.g., SN-38). The combination therapy for treating cancer can have synergistic effect.